Ovid Therapeutics shareholders approve reverse stock split authorization at annual meeting

Ovid Therapeutics Inc.

Elected directors Kevin Fitzgerald and Bart Friedman to three-year terms with >35M votes for each.
Advisory say-on-pay approved, 35.4M for vs 0.9M against (95% of votes cast).
Ratified KPMG as independent auditor for FY2025, 50.8M for vs 0.2M against.
Authorized board to implement reverse stock split at ratio 1:10 to 1:40, at board's discretion (44.2M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.